Patents Assigned to DRG International, Inc.
-
Patent number: 8304197Abstract: The present invention concerns methods for detecting a hepcidin precursor in a sample from a patient and involves contacting the sample with an antibody or fragment thereof that specifically binds to one or more epitopes of a hepcidin precursor amino acid sequence located within amino acids 20-50 of SEQ ID NO: 2.Type: GrantFiled: July 18, 2011Date of Patent: November 6, 2012Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 8304258Abstract: The present invention concerns antibodies specific for the C-terminus of human hepcidin, and related methods and kits for diagnosing and/or treating a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 60 and 84, or, in another embodiment, amino acids 74 and 81, as aligned with the human pre-pro-hepcidin precursor protein, and quantifying the pro-hepcidin and/or mature hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin/mature hepcidin is indicative of the disease condition.Type: GrantFiled: August 23, 2011Date of Patent: November 6, 2012Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko
-
Patent number: 8263352Abstract: The present invention concerns a method of detecting hepcidin, prohepcidin or fragments thereof, by contacting the sample with an antibody or fragment thereof that specifically binds to one or more epitopes contained within amino acids 28-47 of SEQ ID NO:2.Type: GrantFiled: July 8, 2011Date of Patent: September 11, 2012Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Jentzko, Wolfgang Stremmel
-
Publication number: 20120003696Abstract: The present invention concerns antibodies specific for the C-terminus of human hepcidin, and related methods and kits for diagnosing and/or treating a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 60 and 84, or, in another embodiment, amino acids 74 and 81, as aligned with the human pre-pro-hepcidin precursor protein, and quantifying the pro-hepcidin and/or mature hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin/mature hepcidin is indicative of the disease condition.Type: ApplicationFiled: August 23, 2011Publication date: January 5, 2012Applicant: DRG INTERNATIONAL, INC.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko
-
Publication number: 20110287448Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: ApplicationFiled: July 8, 2011Publication date: November 24, 2011Applicant: DRG INTERNATIONAL, INC.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Publication number: 20110275099Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.Type: ApplicationFiled: July 18, 2011Publication date: November 10, 2011Applicant: DRG INTERNATIONAL, INC.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 8003338Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.Type: GrantFiled: December 2, 2009Date of Patent: August 23, 2011Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 7998691Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: GrantFiled: May 24, 2010Date of Patent: August 16, 2011Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Publication number: 20100330595Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: ApplicationFiled: May 24, 2010Publication date: December 30, 2010Applicant: DRG International Inc.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Publication number: 20100086945Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.Type: ApplicationFiled: December 2, 2009Publication date: April 8, 2010Applicant: DRG International Inc.Inventors: Hasan Kulaksiz, Cyrill E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 7649081Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.Type: GrantFiled: September 26, 2006Date of Patent: January 19, 2010Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 7411048Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: GrantFiled: November 19, 2002Date of Patent: August 12, 2008Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Patent number: 7320894Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: GrantFiled: May 19, 2003Date of Patent: January 22, 2008Assignee: DRG International, Inc.Inventors: Hasan Kulaksiz, Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel
-
Publication number: 20040096990Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: ApplicationFiled: May 19, 2003Publication date: May 20, 2004Applicant: DRG International , Inc.Inventors: Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel, Hasan Kulaksiz
-
Publication number: 20040096987Abstract: The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.Type: ApplicationFiled: November 19, 2002Publication date: May 20, 2004Applicant: DRG International, Inc.Inventors: Cyril E. Geacintov, Alfred Janetzko, Wolfgang Stremmel, Hasan Kulaksiz